Mutant-Specific Reagents, Clinical Progress, and High-Purity Reagents for Calmodulinopathy and Calcium Signaling Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CALM2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CALM2 Wild-Type / Mutant (N98S, D130G, F142L) Recombinant Proteins High purity (>95%), Endotoxin controlled. Sequence Verified. Calcium-binding activity preserved. |
View CALM2 Products |
| Gene Delivery | CALM2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and cardiac model construction. |
View CALM2 Products |
| Benchmark Ab | Anti-CALM2 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP. |
View CALM2 Products |
| Validator | CALM2 siRNA Set For allele-specific knockdown verification. |
View CALM2 Products |
| Related Target A | RYR2 (Ryanodine Receptor 2) Primary intracellular calcium release channel; interacts directly with CALM2. Key in CPVT research. |
View RYR2 Products |
| Related Target B | CACNA1C (CaV1.2) L-type calcium channel regulated by CALM2; central to Long QT Syndrome (LQTS) therapeutics. |
View CACNA1C Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mutant vs. WT Differentiation | Sequence-verified mutant proteins (N98S, D130G) with high purity (>95%) for biophysical binding assays. |
| Calcium-Dependent Conformation | Native-like folding verified by mass spectrometry and functional calcium-binding assays. |
| Lack of Controls | Clinical-grade benchmark antibodies and validation-ready siRNA sets included in the portfolio. |
| Off-Target Screening | Homolog panel covering CALM1, CALM2, and CALM3 to verify target specificity. |
Live CALM2/CALM R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CALM2/CALM therapeutics is intensifying, with major players shifting focus from traditional small-molecule inhibitors to gene-editing and allele-specific RNA interference (RNAi). Because Calmodulin (encoded by CALM1, CALM2, and CALM3) shares 100% amino acid sequence identity across all three genes, systemic small-molecule inhibition carries severe off-target cardiac and neurological toxicity risks. As first-generation therapies reach the clinic, the next wave of R&D is targeting allele-specific knockdown of pathogenic mutations (such as N98S and D130G) to treat life-threatening calmodulinopathies like Long QT Syndrome (LQTS) and Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| RNAi / ASO | Alnylam, Ionis Pharmaceuticals | Calmodulinopathy (LQTS, CPVT) | Allele-specific knockdown assays (Need CALM2 mutant/WT validated siRNA and qPCR assays) |
| Gene Editing (CRISPR) | Intellia Therapeutics, Editas Medicine | Severe Arrhythmia (CALM2-mutant) | Stable cell line generation (Need high-titer CALM2 Lentivirus for cardiac cell models) |
| Small Molecule (PPI Inhibitors) | Academic/Consortium-led projects | Heart Failure, Arrhythmia | Protein-Protein Interaction (PPI) assays (Need high-purity CALM2, RYR2, and CACNA1C proteins) |